STATISTICS IN MEDICINE, VOL. 7, 1313–1314 (1988)

AUTHOR INDEX

Aalen, O. O., 1121
Abbott, R. D., 219
Albert, A., 525
Allen, J. R., 395
Altman, D. G., 629
Andersen, P. K., 661
Anderson, K., 205
Anson, J., 895

Bailar, J. C., 1003
Bailey, K., 337
Baker, S. G., 965
Bennett, D. E., 765
Bithell, J. F., 857
Blackwood, L., 975
Blin, P., 1147
Blumenson, L. E., 457
Böhning, D., 865
Breslow, N., 7, 361
Buist, A. S., 11, 685
Buwalda, M., 739
Byar, D., 1243

Canada, A. T., 471
Chastang, C., 1243
Chastang, J. F., 983
Chen, T. T., 671
Chi, G. Y. H., 877
Chilvers, C. E. D., 1165
Choi, S. C., 929
Christensen, F., 639
Clarke, W. R., 47
Clayton, D., 819
Cox, C., 435
Cupples, L. A., 205

D'Agostino, R. B., 205
Dan, B. B., 1003
Davis, C. S., 109
Dawson-Saunders, E. K., 1003
Day, S. J., 1187
Dersimonian, R., 965
Desmonts, J. M., 947
de Stavola, B. L., 1013
de Vet, H. C. W., 1171
Diem, J. E., 19
Dix, D., 377
Dobson, A. J., 613
Dorse, C., 619
Downham, D. Y., 387
Dunn, G., 805
Dwyer, J. H., 177

Elashoff, J. D., 877
Elashoff, R. M., 765
Ellenberg, J. H., 717
Ellenberg, S. S., 571
Ershow, A. G., 363
Espeland, M. A., 403

Fayers, P. M., 1165
Feinleib, M., 177
Fidler, V., 739
Findlay, J. G., 941
Flahault, A., 1147
Freedman, L. S., 1013, 1165

Gail, M. H., 363
Galbraith, R. F., 889
Graubard, B. I., 1087
Green, J., 443
Green, M. S., 519
Greenland, S., 745
Greenwood, R. M., 1165
Groeneveld, H. T., 955

Hafner, K. B., 471
Halperin, M., 289
Hamilton, M. A., 535
Hatton, F., 947
Hayes, R. J., 915
Hazout, S., 1147
Hebel, J. R., 423
Herndon, J. L., 1045
Hirji, K. F., 765
Holme, I., 1109
Hopper, J. L., 581
Hosmer, Jr., D. W., 759
Howel, D., 1157
Hsieh, F. Y., 1195
Hsieh, C.-C., 1073
Hughes, M. D., 1231

Irwig, L. M., 955

Jacob, R. G., 697
Johnson, L. R., 685
Jones, R. H., 1289
Jørgensen, B., 639

Kalbfleisch, J. D., 149
Kannel, W. B., 205
Katz, B. P., 795
Keller, M. B., 727
Khamis, H. J., 591
Kjærsgaard-Andersen, P., 639
Klar, J., 759
Koch, G. G., 109, 471, 877
Korn, E. L., 1087
Kuritz, S. J., 507
Kusek, J. W., 1

Lachenbruch, P. A., 467, 549
Lagakos, S. W., 257
Laird, N. M., 305
Landis, J. R., 109, 507
Lauer, R. M., 47
Lavori, P. W., 727
Lawless, J. F., 149
Lawrence, D. N., 395
Leclerc, A., 983
Lehoczky, J. P., 697
Lemeshow, S., 759
Leppard, P., 483
Lert, F., 983
Lesaffre, E., 525
Letrait, S., 1147
Leverett, D. H., 403
Lipsitz, S., 95
Little, R. J. A., 347
Liukkonen, J. R., 19
Lloyd, C. J., 1297
Logeay, P., 983
Louis, T. A., 29
Low, H. C., 443
Lubin, J. H., 363
Luce, D., 983
Lui, K.-J., 395

Machin, D., 1165
Makuch, R. W., 843
Manton, K. G., 239, 293, 325
Marks, R. G., 1003
Marler, M. R., 697
Marshall, R. J., 1223
Mau, J., 1267
McCamant, L. E., 685
McClatchey, M. W., 1289
Ménarés, J., 1147
Merkouriou, S., 377
Merrill, D. W., 491
Messerer, D., 1139
Miller, M. E., 109
Milner, P. C., 1061
Montasser, M., 443
Moore, II., D. H., 765
Moussa, M. A. A., 559
Mulshine, J., 843
Muñoz, A., 59
Murphy, W. C., 403
Murray, G. D., 941

Nagelkerke, N. J. D., 739
Naus, J., 1171
Newcombe, R. G., 1179
Newman, S. C., 787
Norwood, P. K., 1023

O'Neill, R. T., 1279
O'Neill, T. J., 483
Ozminkowski, R. J., 1207

Palmer, N., 1165
Parker, R. A., 1031
Pedersen, N. W., 639
Peterman, T. A., 395
Petri, H., 1171
Piantadosi, S., 1243
Pocock, S. J., 1231
Prentice, R. L., 275
Province, M. A., 185

Rao, D. C., 185
Rinaldi, M. G., 535
Robins, J. M., 773
Roloff, D. W., 1207
Rosenberg, P. S., 843
Rosner, B., 59
Rothenberg, R. B., 1031
Royston, J. P., 629
Rücker, G., 1139

Sampson, A. R., 1023
Schemper, M., 1257
Schluchter, M. D., 317
Schmidt, S. A., 639
Schulman, J., 491
Segal, M. R., 601
Self, S. G., 275
Selvin, S., 491
Shapiro, A. P., 697
Shrager, R., 571
Simon, R., 571
Simpkin, J. M., 387
Speizer, F. E., 95, 601
Stablein, D. M., 929
Stallard, E., 239, 293
Stiller, C. A., 857
Stone, R. A., 649
Stram, D. O., 139
Stroup, D. F., 1045

Tager, I. B., 601
Tallis, G. M., 483
Thacker, S. B., 1045
Thall, P. F., 571
Tiret, L., 947

Urquhart, J., 1171

Valleron, A. J., 1147
Verran, J. A., 1003
Vollmer, W. M., 11, 685
Vourc'h, G., 947

Walter, S. D., 1073
Ware, J. H., 95
Wei, L. J., 139
Weiss, S. T., 601
Westlake, A. J., 1165
Whitehead, J., 619
Whittemore, A. S., 223
Wilson, P. D., 73, 417, 423
Woodbury, M. A., 239, 293, 325
Woodrow, J. C., 443
Wortman, P. M., 1207
Wu, M. C., 1, 337

Yashin, A. I., 325
Young, G. P., 581

Zeger, S. L., 161

STATISTICS IN MEDICINE, VOL. 7 1315–1323 (1988)

SUBJECT INDEX

((L) indicates subject discussed in Letter to the Editors)

Accident and emergency services, 1061
Acquired Immunodeficiency Syndrome (AIDS), 395, 549
Adjusted rates, 223
Adverse drug reaction, 1023, 1171
Affective illness, 727
Age–Period–Cohort model, 685
Age standardized rates, 223
Aggregate data, 613
Aggregation, familia, 185
Agreement, intrinsic, 639
AIDS, 395, 549
Alcohol, 1223
Algorithm, EM, 19, 305, 819
Algorithm, transformation, 491
Allocation rule, β-confidence, 525
Allocation, treatment, 471, 559
Amosite miners, 955
Anaesthesia, 947
Analgesics, 435, 1179
Analysis of variance, 467, 471
Angina, 519
Angle transformation, 865
Antidepressants, 1171
Antigens, HLA, 443
Antimicrobial drugs, 535, 745
Antimicrobic susceptibility test, 535
Arcsine transformation, 865
ARMA model, 29, 357, 1045, 1061
Arthritis, psoriatic, 443
Asbestos, 955
Assay, dilution, 535
Assay, drug, 805
Association, measures of, 591
Association, tests of, 257, 443, 1297
Atenolol, 697
Atrial Pacing, 109
Attributable risk, 507, 717, 1073
Attributable risk, confidence interval, 507
Autocorrelation, 417, 423, 1045, 1061
Autoregression model, 19, 29, 59, 73, 87, 161, 177, 239, 317, 357, 417, 423, 1045, 1061
Azathioprine, 629

Baby unit, intensive care, 1207
Balanced covariate in clinical trials, 1243
Balance of treatments in clinical trials, 471
Bartlett's correction, 387
Baseline observation, clinical trials, 1203(L)
Bayesian inference, 697, 1223, 1231, 1289
Berkson model, 257, 289, 297
Beta distribution, 457, 1031, 1223
Betrend model, 185
Bias, dropout, 29
  estimation, 1231, 1243
  length, 395
  prediction, 843
  publication, 1207, 1231
  selection, 417, 423, 727, 1179, 1203(L), 1207
  withdrawal, 941
Bilirubin, serum, 629
Binary exposure, 773, 1073
Binary response, 457, 571, 671, 773, 843, 929, 955, 975, 1187, 1267, 1297
Biomedical journals, statistics in, 1003
Birth weight, 1207
Biserial correlation coefficient, 955
Blood pressure, 47, 87, 185, 199, 205, 219, 275, 423, 629, 697, 941, 1087, 1109
Blood transfusion, 395
BMDP, 1257
Body size, 47
Bonferroni method, 467
Book Reviews
  A. Albert and E. K. Harris, *Multivariate Interpretation of Clinical Laboratory Data*, 1308
  P. Armitage and G. Berry, *Statistical Methods in Medical Research*, 817
  J. C. Bailar and F. Mosteller (Eds), *Medical Uses of Statistics*, 1001
  M. Bland, *An Introduction to Medical Statistics*, 1307
  R. C. Elston and W. D. Johnson, *Essentials of Biostatistics*, 1204
  J. L. Fleiss, *The Design and Analysis of Clinical Experiments*, 454
  L. Kish, *Statistical Designs for Research*, 455
  Living with Risk: the BMA Guide, 453
  D. Machin and M. J. Campbell, *Statistical Tables for the Design of Clinical Trials*, 1307
  C. L. Meinert, *Clinical Trials: Design, Conduct and Analysis*, 545
  K. J. Rothman, *Modern Epidemiology*, 818

Bootstrap, 29, 601, 843
Box Jenkins model, 1045, 1061
Bronchitis, 11
Burns, 975

Categorical response, 93–173, 581, 965
Calcification, 619
Cancer, 239, 857
  bladder, 1013
  breast, 619, 1121
  childhood, 649, 857
  incidence, 223
  leukemia, 491, 649, 1121, 1139
  lung, 223, 297, 325, 483, 491, 843
  lymphoma, 1139
  melanoma, 765
  mortality, 223, 325
  oesophagus, 507, 1223
  vagina, 1223
Cancer registry data, 483
Candida albicans, 535
Capacity, forced vital, 11, 685
Carcinogenesis model, multistage, 223
Cardiovascular disease, 205, 219, 239, 613, 717, 1109
Caries, dental, 403
Carlos–Senning model, 403
Cartograms, 491
Carryover effects, crossover trials, 471, 1099(L)
Case-cohort study, 149, 275
Case-control study, 223, 275, 507, 619, 745, 759, 765, 819, 857, 1073, 1087, 1223, 1279
  power, 363, 759, 1279
  size, 363, 759, 1279
  type 1 error, 363, 759, 1279
Categorical data, 975, 983
Cause-specific failure, 965
Censored observations, 203–302, 325, 337, 347, 395. 483, 559, 619, 661, 819, 1013, 1121, 1139, 1243, 1257
Censoring models, 337, 347, 357
Cerebral palsy, 717
Change, analysis of, 337, 915
Change and initial value, 915
Change-point process, 387
Chest radiography, 955
Chlamydia trachomatis, 795
Chlorthalidone, 697
Cholesterol, 139, 519, 717
Cigarette smoking, 11, 59, 95, 223, 289, 297, 601, 685
Circadian rhythm, 423, 697
Circularity, 471
Cirrhosis, 629
Classification, 519, 525, 745, 1073
Classification error, 257, 403, 525, 745, 955

Clinical chemistry, 377
Clinical trials, accrual, 559
  allocation of treatment, 471, 559
  analgesics, 435
  balanced covariate, 1243
  balance of treatments, 471
  baseline observation, 1203(L)
  carryover effects, 471, 1099(L)
  clinical equivalence, 1267
  combination of, 889, 1109
  COMPACT computer package, 1165
  covariate adjustment, 1243
  crossover, 471, 1099(L)
  data monitoring, 1165, 1231
  data quality, 1165
  delayed randomization, 1013
  design, 457, 467, 471, 559, 571, 877, 1179, 1187, 1231, 1243
  deviations from treatment, 1179
  duration of treatment, 1013
  early termination of, 571, 1231
  efficacy of treatment, 1179, 1231, 1243, 1257, 1267
  equivalence, clinical, 1267
  error rate, type I, 457, 559, 571, 1231
  explanatory, 1179
  gastroenterology, 581
  group sequential, 571, 1231
  hypertension, 941, 1109
  interim analysis, 451(L), 1231
  meta-analysis, 889, 1109
  missing data, 941
  overview of, 889, 1109
  parallel group design, 1187
  patient selection, 1179
  phase 2, 571
  placebo response, 1187, 1203(L)
  pooling, 889, 1109
  power, 457, 559, 571, 1099(L), 1179, 1187, 1231
  pragmatic, 1179
  prevention, 275
  qualitative interaction, 1257
  quantitative interaction, 1257
  randomization, 559, 1013, 1179
  randomized consent design, 1179
  recruitment, 559
  regression to the mean, 1203
  size, 457, 559, 571, 1099(L), 1179, 1187, 1231
  stopping rules, 571, 1231
  stratification, 559, 745, 843, 1257
  strength of evidence, 1267
  three-period crossover, 471
  treatment allocation, 471, 559
  treatment balance, 471
  treatment-covariate interaction, 843, 1257
  treatment deviations, 1179

treatment duration, 1013
treatment period interaction, 1099(L)
two period crossover, 1099(L)
two-stage design, 571
ulcer recurrence, 877
withdrawals, 941
Zelen's design, 1179
Cluster, disease, 491
randomization, 1195
space–time, 491, 1147
spatial, 1157
Coefficient of determination, 519
Cohort study, 47, 149, 205, 223, 239, 275, 325, 685, 745, 759, 773, 819, 1279
power, 759, 1279
sample size, 759, 1279
Colitis, 581
Community intervention study, 1195
COMPACT computer package, 1165
Comparison of proportions 457, 929, 1187
Competing risks model, 239, 819, 965, 1121
Components of variance, 1195
Compound mixture model, 483
Computer database, 1165
Computer packages, BMDP, 1257
COMPACT, 1165
GLIM, 443
SAS, 109, 1257
Concentration, threshold, 535
Confidence distribution, 1267
Confidence ellipsoid, 525
Confidence interval, adverse drug reaction rate, 1023
attributable risk, 507
odds ratio, 745, 889
proportion, 865
protective efficacy of vaccine, 1279
rate, 865
risk difference, 773
risk ratio, 773
Confounding, neighbourhood, 1087
Congenital malformation, 387
Consonance interval, 1267
Contingency coefficient, 591
Contingency tables, 109, 591, 1297
Contingency tables, missing data, 109
Continuation ratio model, 435
Continuity correction, 929
Contraceptive, oral, 275
Contrast, orthogonal, 467
Coronary artery disease, 519
Correction, Bartlett's, 387
Correlation coefficient, 717
biserial, 955
intracluster, 1195
serial, 697
tetrachoric, 955
Correspondence analysis, 983
Cosinor analysis, 697
Counting process, 275, 819
Covariance structure, repeated measures, 29, 87, 109, 185, 199, 317, 357, 471, 601
Covariate adjustment, clinical trials, 1243
Covariate, time dependent, 139, 169, 205, 297
Cox proportional hazards model, 205, 257, 289, 297, 559, 661, 819, 1013, 1243, 1257
Cramer–Von Mises statistic, 1031
Creatine kinase, 377
Creatinine, 629
Credible interval, odds ratio, 1223
Crocidolite miners, 955
Crossover clinical trials, 471, 1099(L)
Cross-sectional study, 685, 1087
Cumulative logit model, 109
Cusum techniques, 629, 997(L), 998(L)

Dapsone, 739
Data aggregation, 613
Data monitoring, clinical trials, 1165, 1231
Data quality, clinical trials, 1165
Database computer, 1165
Decision analysis, 1289
Demographic maps, 491
Density equalized map projections, 491
Dental caries, 403
Depression, 727
Dermatoglyphics, 591
Dermatomyositis, 1157
Design, assay, 805
Design of clinical trials, 457, 467, 471, 559, 571, 877, 1179, 1187, 1231, 1243
Determination, coeffiecient of, 519
Diabetes, 661, 671
Diagnosis, 377, 403, 423, 525, 549, 727, 1289
Diagnostic errors, 257, 403, 525, 745, 955
Diagnostic tests, 403, 519, 549, 727, 739, 1289
Dichotomous exposure, 773, 1073
Dichotomous response, 457, 571, 671, 773, 843, 929, 955, 975, 1187, 1262, 1297
Diet, 1087
Diethylstilbestrol, 1223
Diffusion model, 1147
Digoxin, 629
Disability, 325
Disability model, 661
Discriminant analysis, logistic, 525
Discriminatory power, 519
Disease cluster, 491
Distribution, beta, 457, 1031, 1223
confidence, 1267
exponential, 559, 1243
mixing, 1121
Pareto, 483
Poisson, 387, 1023, 1121
spatial, 491

Weibull, 395, 1121, 1243
D-optimal designs, assays, 805
Dose-response relationship, 805, 955
Dropout bias, 29
Drug reactions, adverse, 1023, 1171
Drug surveillance, post marketing, 1023
Drugs, prescription, 1171
Duodenal ulcer, 877
Duration of treatment, comparison of, 1013

Early termination of clinical trials, 571, 1231
Editors, Biomedical Journals, 1003
Educational Attainment, 435
Efficacy, treatment, 1179, 1231, 1243, 1257, 1267
  vaccination, 1279
Efficiency of monitoring systems, 997(L), 998(L)
Elisa test, 549
EM algorithm, 19, 305, 819
Empirical Bayes model, 697
Emphysema, 11
Endoscopy, 877
Environmental risks, 491, 649
Epidemic, influenza, 1147
Epidemiological methods, 1–361, 363, 387, 395, 403, 417, 435, 483, 491, 507, 519, 601, 613, 619, 649, 661, 685, 697, 717, 745, 759, 765, 773, 819, 843, 955, 965, 975, 1073, 1087, 1223
Epidemiology, 1–361, 423, 661, 857, 1045, 1109, 1147
  genetic, 185, 199, 591
  heart disease, 205, 219, 239
Equivalence, clinical in trials, 1267
Error, classification, 257, 403, 525, 745, 955
  measurement, 177, 257, 275, 915, 955
Error rate, type I, case-control study, 363, 759, 1279
  censoring models, 337, 357
  clinical trials, 457, 559, 571, 1231
  cluster randomization, 1195
  experimentwise, 1031
  test for interaction, 467
Error, statistical, 1003
Erythrocyte count, 377
Estimation bias, clinical trials, 1231
Event history data, 95, 149, 819
Evidence, strength of in clinical trials, 1267
Exact test, Fisher, 1297
Excess risk, 649
Experimental design, assays, 805
Experimentwise type I error, 1031
Explanatory clinical trials, 1179
Exponential distribution, 559, 1243
Exponential family models, 435, 1297
Exposure, continuous, 363
Exposure, dichotomous, 773, 1073

Familial aggregation, 185
Family studies, 727
Fingerprint pattern, 591
Fisher exact test, 1297
Flunarizine, 1171
Fluoride, 403
Fluorosis, dental, 403
Fokker–Planck equation, 239
Follow-up, passive, 483
Follow-up studies, 1–361, 417, 423, 601, 671, 685, 745, 773
Forced expiratory volume, 11, 19, 337, 601, 685
Forced vital capacity, 11, 685
Fraction, prevented, 1073
Frailty model, 819, 1121
Framingham heart study, 205, 219, 239

Gallstones, 139
Gamma mixing model, 1121
Gastroenterology, 581
Generalized linear model, 29, 95, 139, 819, 1257
Genetic epidemiology, 185, 199, 591
Genetics, human, 185, 443, 591
German ALL/AUL study, 1139
GLIM, 443
Graphical presentation of odds-ratios, 889
Group randomization, 1195
Group sequential methods, 571, 1231
Grouped data, 535
Growth model, 73, 87, 305, 317

Hardy–Weinberg equilibrium, 591
Hazard function, 239, 325, 819
Hazards model, Cox proportional, 205, 257, 289, 297, 559, 661, 819, 1013, 1243, 1257
Head injury, 929
Health survey, 983
Health care, 1061
Heart disease, 205, 219, 239, 613, 717, 1109
Heterogeneity, study, 889, 1109, 1207
Hexagonal mosaic, 1157
Hip joint, 639
HIV, 395, 549
HLA antigens, 443
Homogeneity, test of marginal, 109
Hormone receptors, 805
Hosmer–Lemeshow statistic, 519, 947
Hospital admissions, 787
Human genetics, 185, 443, 591
Human immunodeficiency virus (AIDS), 395, 549
Hypertension, 47, 423, 697, 915, 941, 1109

Hypertension Detection and Follow-up Program (HDFP), 423
Hypospadias, 387

Idiometric regression, 697
Ignorable non-response model, 305, 357
Illness-death model, 149, 661
Impact of Hypertension Information Project (IHI), 423
Inborn–outborn status, 1207
Incidence, cancer, 223
Incidence, disease, 149, 403, 507, 727
Incidence rates, 403, 727
Incubation period, TA-AIDS, 395
Independence, statistical, 1289
Independent increments model, 29
Index, morbidity, 787
  plot, 629
  risk, 947
  Sullivan's, 787
  Youden, 519
Infectious disease, 1147
Influenza, 1045, 1147, 1267
Inheritance, 185, 199
Inhibitory concentration, minimum, 535
Instrumental variables, 739
Intensive care unit, neonatal, 1207
Intention to treat, 1179
Interaction, analysis of variance, 467
  treatment-period, 1099(L)
  statisticians and editors, 1003
  treatment covariate, 843, 1257
Interim analysis in clinical trials, 451(L), 1231
International Society for Clinical Biostatistics (ISCB) Eighth International Conference, Gothenberg Committees, 1107
  Papers, 1109–1176
  Preface, 1105
Interobserver variation, 639, 955
Interrater reliability, 403
Interval censored data, 1139
Intervention study, community, 1195
Intracluster correlation, 1195
Intrinsic agreement, 639
Irradiation, X-ray, 857
Isotonic regression, 649

Jackknife, 1257
Journals, statistics in medical, 1003
Jump process, multivariate, 325

Kalman filter, 73
Kaplan–Meier estimator, 1139
Kappa statistic, 639
Kiel lymphoma study, 1139

Laboratory determinations, reference values, 377
Laboratory monitoring, 377
Latent variables, 177, 975
Laws, mortality, 895
Lead, blood, 1087
Length bias, 395
Leprosy, 739
Life expectancy, 895
Life table, 787, 895
Ligand binding, 805
Linear model, generalized, 29, 95, 139, 819, 1257
Lineweaver–Burk plot, 805
Liver disease, 525
Liver function, 671, 843
Liver metastases, 843
LLP model, 403
Loggers, Ash, 685
Logistic regression model, 95, 161, 199, 205, 223, 257, 289, 519, 525, 739, 765, 819, 843, 947, 983, 1187
Logistic transformation, 443
Logit model, 109, 435
Log–linear model, 161, 305, 347, 403, 591, 639, 671, 819, 965, 975
Logrank test, 559
Longitudinal data, 1–361, 417, 423, 471, 601, 671, 685, 745, 965, 975
Lu model, diagnostic inconsistency, 403
Lung function, 11, 19, 29, 59, 139, 337, 601, 685

McNemar statistic, 929
Majority rule, 549
Mantel–Haenszel statistic, 109, 507, 591, 1109
Maps, demographic, 491
Marginal homogeneity, test of, 109
Markov model, 95, 169, 205, 325, 347, 671, 819, 877, 965
Markov process, 581, 661, 787
Mean, regression to the, 915, 1203(L)
Mean-square contingency coefficient, 591
Measurement error, 177, 257, 275, 915, 955
Medical journals, statistics in, 1003
Mendelian segregation model, 591
Meta-analysis, 889, 1109, 1207
Michaelis–Menton kinetics, 805
Miners, 955
Minimum inhibitory concentration, 535
Misclassification, 257, 403, 525, 745, 955, 1073
Mismodelling, 257
Missing data, clinical trials, 941
  contingency tables, 109
  longitudinal studies, 29, 59, 95, 109, 139, 177, 185, 219, 303–360, 403, 483, 671
  paired observations, 929
  surveys, 727

Mixing distribution, 1121
Mixture model, 483, 1031
Model, age–period–cohort, 685
  ARMA, 29, 357, 1045, 1061
  autoregression, 19, 29, 59, 73, 87, 161, 177, 239, 317, 357, 417, 423, 1045, 1061
  Bayes, empirical, 697
  Berkson, 257, 289, 297
  betrend, 185
  Box Jenkins, 1045, 1061
  Carlos–Senning, 403
  censoring, 337, 347, 357
  competing risks, 239, 819, 965, 1121
  continuation ratio, 435
  Cox proportional hazards, 205, 257, 289, 297, 559, 661, 819, 1013, 1243, 1257
  cumulative logit, 109
  diagnostic inconsistency, 403
  diffusion, 1147
  disability, 661
  empirical Bayes, 697
  exponential family, 435, 1297
  frailty, 819, 1121
  gamma mixing, 1121
  generalized linear, 29, 95, 139, 819, 1257
  growth, 73, 87, 305, 317
  idiometric regression, 697
  illness–death, 149, 661
  independent increments, 29
  isotonic regression, 649
  linear regression, 19, 59, 257, 601, 805
  LLP, 403
  logistic regression, 95, 161, 199, 205, 223, 257, 289, 519, 525, 739, 765, 819, 843, 947, 983, 1187
  logit, 109, 435
  log–linear, 161, 305, 347, 403, 591, 639, 671, 819, 965, 975
  Lu, 403
  Markov, 95, 169, 205, 325, 347, 671, 819, 877, 965
  Mendelian segregation, 591
  mixture, 483, 1031
  moving average, 29, 357, 795, 1045, 1061
  multistage carcinogenesis, 223
  multistate, 149, 661, 819, 965
  non-response, 305, 347, 357
  Poisson regression, 223, 819
  probit, 1187
  proportional odds, 95, 109
  random coefficient regression, 697
  random effects, 29, 87, 317, 337, 819
  random walk, 581
  Rasch, 975
  retrend, 185
  stochastic, 95, 239, 293, 325, 581, 661, 671
  symmetry, 671
  validation, 947
  weighted non-linear regression, 59
Monitoring data, 1165, 1231
Monitoring, laboratory, 377
Monitoring systems, rare event, 997(L), 998(L)
Monte Carlo simulation, 59, 275, 387, 507, 581, 795, 865, 915, 1171, 1231, 1243
Morbidity, hidden, 325
Morbidity index, 787
Mortality, 149, 239, 293, 325, 661, 787, 895, 1045
Mortality, cancer, 223, 325
  cause-specific, 965
  heart disease, 205, 219, 613
  relative, 661
Mosaic, hexagonal, 1157
Moving average, 29, 357, 795, 1045, 1061
Multiple comparisons, 467, 1031
Multiple diagnostic tests, 1289
Multiple linear regression model, 601
Multiple reading, 549
Multistage carcinogenesis model, 223
Multistate model, 149, 661, 819, 965
Muscatine Study, 47
Muscle disorders, inflammatory, 1157
Muscle fibres, 1157
Myocardial infarction, 205, 219, 239, 613, 717

National Cooperative Gallstone Study (NCGS), 139
National Health and Nutrition Examination Survey, 1087
National Heart, Lung and Blood Institute, 1
Nearest neighbourhood, 601
Neonatal intensive care, 1207
Neonatal survival, 1207
Nephropathy, 661
Neurotransmitters, 805
Non-linear regression model, weighted, 59
Non-response models, 305, 347, 357
Nuclear plants, 491, 649
Nurses health survey, 983
Nutrition, 1087

Observational study, 1–361, 417, 423, 601, 671, 685, 745, 773, 1139
Obstetric X-raying, 857
Odds ratio, 363, 507, 727, 745, 759, 765, 857, 889, 947, 1073, 1109, 1207, 1223, 1243, 1279
  confidence interval, 745, 889
  credible interval, 1223
  graphical presentation, 889
Oesophagitis, 581
Oldham plot, 915
Oral contraceptives, 275
Ordered multinomial response, 435
Ordered response categories, 435, 581
Ordinal scales, 109

Organs, paired, 619
Orthogonal contrast, 467
Osteoarthrosis, 639
Outliers, 697
Overview, clinical trials, 889, 1109
  graphical presentation, 889
  non-randomized studies, 1207

Pain, relief, 435, 1179
Paired observations, 619, 929
Paired organs, 619
Parallel group design, 1187
Pareto distribution, 483
Patel–Hoel test, 1257
Path analysis, 185
Pattern, spatial, 1157
Penetrance, genetic, 591
Pentobarbital metabolism, 471
Percentile plot, 377
Permutation test, 795
Person-years method, 205, 819
Phase 2 clinical trials, 571
Phi coefficient, 717
Placebo response, 1187, 1203(L)
Plot, index, 629
  radial, 889
  Lineweaver–Burk, 805
  Oldham, 915
  percentile, 377
Plutonium exposure, 491
Pneumoconiosis, 955
Pneumonia, 1045
Poisson distribution, 387, 1023, 1121
Poisson process, 325, 819
Poisson regression model, 223, 819
Pollution, environmental, 491
Polymyositis, 1157
Polynomial representation, survivorship curve, 895
Pooling, clinical trials, 889, 1109
  non-randomized studies, 1207
Postmarket surveillance, 1023
Power, case-control study, 363, 759, 1279
  censoring models, 337, 357
  clinical trials, 457, 559, 571, 1099(L), 1179, 1187, 1231
  cluster randomization, 1195
  cohort studies, 759, 1279
  discriminatory, 519
  runs test, 795
  test for interaction in analysis of variance, 467
P-plot, 1031
Pragmatic clinical trials, 1179
Prediction bias, 843
Prediction interval, 773
Prediction rule, 843
Predictive value, diagnostic tests, 549, 1289
Prescription drugs, 1171
Prescription sequence analysis, 1171
Presentation, graphical, 889
Prevented fraction, 1073
Prevention clinical trials, 275
Principal component analysis, 983
Probit model, 1187
Process, change-point, 387
  counting, 275, 819
  jump, 325
  Markov, 581, 661, 787
  Poisson, 325, 819
Prognostic factors, 11, 59, 203–302, 325, 363, 403, 507, 601, 613, 619, 717, 843, 857, 947, 1073, 1223, 1243
Progressive disease, 403
Projections, map, 491
Proportion, confidence interval, 865
Proportional hazards model, 205, 257, 289, 297, 559, 613, 661, 819, 1013, 1243, 1257
Proportional odds model, 95, 109
Proportions, comparison of, 457, 929, 1187
Proportions, correlated, 929
Protective efficacy of vaccination, 1279
Psoriasis, 443
Publication bias, 1207, 1231
Pulmonary function, 11, 19, 29, 59, 139, 337, 601, 685

Qualitative interaction, clinical trials, 1257
Quality of data in clinical trials, 1165
Quantitative interaction, clinical trials, 1257

Radial plot, 889
Radiation, 491, 649
Radiography, chest, 955
Radiological assessment, 639
Random agreement, 639
Random coefficient regression model, 697
Random effects model, 29, 87, 317, 337, 819
Random walk model, 581
Randomization, 559, 1013, 1179
Randomization, group, 1195
Randomized clinical trials see clinical trials
Randomized consent design, 1179
Rasch model, 975
Rates, adverse drug reaction, 1023
Rates, age standardized, 223
Rates, confidence interval, 865
Rates, incidence, 403, 727
Ratio model, continuation, 435
Ratio, odds, 363, 507, 727, 745, 759, 765, 857, 889, 947, 1073, 1109, 1207, 1223, 1243, 1279
Ratio, risk, 507, 1223, 1231
Ratio, weight/height, 73

Receptor assay, 805
Reference range, clinical chemistry, 377
Reference region, 649
Registry data, cancer, 483
Regression, Cox proportional hazards model, 205, 257, 289, 297, 559, 661, 819, 1013, 1243, 1257
  idiometric, 697
  isotonic, 649
  model, logistic, 95, 161, 199, 205, 223, 257, 289, 519, 525, 739, 765, 819, 843, 947, 983, 1187
  model, Poisson, 223, 819
  model, weighted non-linear, 59
  random coefficient, 697
  to the mean, 915, 1203(L)
  weighted linear, 19
Relative efficiency, 59, 997(L), 998(L)
Relative mortality, 661
Relative risk, 275, 363, 507, 649, 717, 759, 819, 857, 1073, 1121, 1279
Relaxation therapy, 697
Reliability coefficient, 955
Repeated measurements 9–361, 417, 423, 471, 601, 671, 685, 745, 965, 975
Respiratory medicine, 95
Retrend model, 185
Retrospective study, 149, 363
Review, statistical, 1003
Rhythm, circadian, 423, 697
Risk, attributable, 507, 717, 1073
  difference, confidence interval for, 773
  excess, 649
  factors, 11, 59, 203–302, 325, 363, 403, 507, 601, 613, 619, 717, 843, 857, 947, 1073, 1087, 1223, 1243
  index, multifactorial, 947
  model, competing, 239, 819, 965
  ratio, 507, 1223, 1231
  ratio, confidence interval, 773
  relative, 275, 363, 507, 649, 717, 759, 819, 857, 1073, 1121, 1279
Risks, environmental, 649
Rocky flats plant, 491
Runs test, 795

Sample size, case-control study, 363, 759, 1279
  censoring models, 337, 357
  clinical trials, 457, 559, 571, 1099(L), 1179, 1187, 1231
  cluster randomization, 1195
  cohort study, 759, 1279
  estimation of rates, 865
  protective efficacy of vaccine, 1279
  test for interaction, 467
SAS, 109, 1257
Scheffe method, multiple comparisons, 467
Score statistic, 149, 363
Screening, 417, 423, 1289
Segregation model, Mendelian, 591
Selection bias, 417, 423, 727, 1179, 1203(L), 1207
Selection of variables, 765, 947
Sellafield Reprocessing Plant, 649
Sensitivity of diagnostic tests, 519, 549, 727, 739, 1289
Sequential clinical trials, group, 571, 1231
Sequential diagnostic rule, 549
Serial correlation, 697
Serial dilution assay, 535
Serial observations, 581
Serum titre assay, 535
Services, accident and emergency, 1061
Sets surveillance technique, 997(L), 998(L)
Shift work, nurses, 983
Shrinkage, 1231
SIDS, 745
Significance level, adjusted, 649
Simulation, Monte Carlo, 59, 275, 387, 507, 581, 795, 865, 915, 1171, 1231, 1243
Six Cities study, 139
Sizewell Nuclear Plants, 649
Skin conditions, 109
Smoking, 11, 59, 95, 223, 289, 297, 601, 685
Smoothed data, 795
Smoothing methods, 601, 843
Smoothing span, 601
Space–time cluster, 491, 1147
Spatial distribution, 491
Spatial pattern, 1157
Special care baby unit, 1207
Specificity of Diagnostic tests, 519, 549, 727, 739, 1289
Sphericity, 471
Spirometry, 11, 19, 685
Spliced smoothing, 601
Standardized rates, 223
Stationarity, Markov chain, 671
Statistical errors, 1003
Statistical independence, 1289
Statistical review, 1003
Statistics in medical journals, 1003
Stepwise testing procedure, 139, 843
Stochastic model, 95, 239, 293, 325, 581, 661, 671
Stool frequency, 581
Stopping rules for clinical trials, 571, 1231
Stratification, 559, 745, 843, 1087, 1195, 1257
Study heterogeneity, 889, 1109, 1207
Sudden infant death syndrome (SIDS), 745
Sullivan's index, 787
Surveillance, postmarketing, 1023
Surveillance system, 997(L), 998(L)
Survey, health, 983, 1087

Surveys, non-response in, 727
Survival analysis, 203–302, 325, 337, 347, 395, 483, 559, 619, 661, 819, 1013, 1121, 1139, 1243, 1257
Survivorship curve, 895
Susceptibility test, antimicrobic, 535
Symmetry model, 671

Temporal trend, 185, 239, 629
Termination of clinical trials, 571, 1231
Test, association, 257, 443
  diagnostic, 403, 519, 549, 727, 739, 1289
  Elisa, 549
  Fisher exact, 1297
  interaction in analysis of variance, 467
  logrank, 559
  marginal homogeneity, 109
  Patel–Hoel, 1257
  permutation, 795
  runs, 795
  susceptibility, 535
  van Elteren, 471
  Wilcoxon, 471
Tetrachoric correlation, 955
Three period crossover trial, 471
Threshold concentration, 535
Time dependent covariate, 139, 169, 205, 297
Time series analysis, 29, 59, 317, 1045, 1061
Toluene diisocyanate, 19
Tracking, 47
Transformation, algorithm, 491
Transformation, angle, 865
  arcsine, 865
  logistic, 443
Transfusion, blood, 395
Transient response, 965
Transition intensity, 661
Treatment, adverse effects, 1023
  allocation, 471, 559
  balance, 471
Treatment–covariate interaction, 843, 1257
Treatment duration, comparison of, 1013
  efficacy, 1179, 1231, 1243, 1257, 1267
Treatment–period interaction, 1099(L)
Trend, temporal, 185, 239, 629
Truncation, 915
Turnbull estimator, 1139
Two-period crossover trial, 1099(L)
Two-stage design, clinical trials, 571

Ulcer recurrence, 877, 1187
Unanimity rule, 549
Utility, 1289

Vaccination, efficacy, 1279
van Elteren test, 471
Variable, selection, 765, 947
Variance, analysis of, 467, 471
Variance, components, 1195
Variation, inter-observer, 403, 639, 955
Variation, within subject, 417, 423, 915
Volume, forced expiratory, 11, 19, 337, 601, 685

Wald statistic, 109
Weibull distribution, 395, 1121, 1243
Weight, birth, 1207
Weight/height ratio, 73
Weighted linear regression, 19
Weighted non-linear regression model, 59
Wheeze, persistent, 95
Wilcoxon test, 471
Withdrawal bias, 941
Workshop on Methods for Longitudinal Data Analysis in Epidemiological and Clinical Studies
  analysis of data with missing values, 303–360
  committees, 1
  editors, 5
  methods for analysing repeated measurements, 9–92
  preface, 1
  proceedings, 1–361
  repeated categorical response, 93–173
  reviewers, 5
  risk factors and survival, 203–302
  speakers and discussants, 3, 4
  special topics, 175–202
  sponsors, 1
Workshop on Statistical Issues in Longitudinal Studies of Health, Berlin, 23–26 June 1986, Report, 177

X-ray irradiation, 857

Yale Health and Aging Project (YHAP), 965
Youden index, 519

Zelen's design, clinical trials, 1179

Statistics in Medicine

Editors
T. Colton
L. S. Freedman
A. L. Johnson
D. Machin

Volume 7 1988

WILEY
Chichester · New York · Brisbane · Toronto · Singapore
A Wiley–Interscience Publication

ISSN 0277–6715

Statistics in Medicine

EDITORS

Theodore Colton,
Boston University School of Public Health, 80 East Concord Street, Boston, Massachusetts 02118, U.S.A.

Laurence Freedman
902 South Belgrade Road, Silver Spring, Maryland 20902, U.S.A.

Tony Johnson and David Machin,
Medical Research Council, 5 Shaftesbury Road, Cambridge CB2 2BW, U.K.

EDITORIAL BOARD

R. D'Agostino
Dept. of Mathematics, Boston University, 264 Bay State Road, Boston, MA 02215, USA

D. G. Altman
Medical Statistics Laboratory, Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK

P. Armitage
Department of Biomathematics, 5 South Parks Road, Oxford OX1 3UB, UK

J. R. Assenzo
Upjohn Research Laboratories, Kalamazoo, Michigan 49001, USA

N. T. J. Bailey
Division d'Informatique Médicale, Hôpital Cantonal Universitaire, 24, rue Micheli-du-Crest, 1211 Genève 4, Switzerland

M. Baum
Dept. of Surgery, King's College Hospital Medical School, Denmark Hill, London SE5 8RX, UK

C. Begg
Division of Biostatistics and Epidemiology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115

V. Beral
London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

R. Brookmeyer
Department of Biostatistics, School of Hygiene & Public Health, Johns Hopkins University, Baltimore, MD 21205, USA

B. W. Brown, Jr
Division of Biostatistics, Stanford Medical Center, Stanford, CA 94305, USA

C. R. Buncher
Dept. of Epidemiology and Biostatistics, University of Cincinnati Medical Center, Mail Location 183, Cincinnati, OH 45267, USA

C. Chastang
Université Paris VII, Faculté de Médecine Lariboisière Saint Louis, Département de Biostatistique et Informatique Médicale, Hôpital Saint Louis, 1 av. Claude Vellefaux, 75475 Paris Cedex 10, France.

D. Clayton
Dept. of Community Health, Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE1 5WW, UK

K. Dietz
Universität Tübingen, Institut für Medizinische Biometrie, Westbahnhofstrasse 55, 7400 Tübingen 1, Germany

A. Donner
Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada N6A 5B7

B. S. Everitt
Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK

A. J. Fox
Dept. of Mathematics, The City University, Northampton Square, London EC1V 0HB, UK

M. H. Gail
Biostatistics Branch, National Cancer Institute, Bethesda, MD 20892, USA

S. M. Gore
MRC Biostatistics Unit, 5 Shaftesbury Road, Cambridge CB2 2BW, UK

E. R. Greenberg
Dept. of Community Medicine, Dartmouth Medical School, Hanover, NH 03755, USA

S. Greenland
Division of Epidemiology, UCLA School of Public Health, Los Angeles, CA 90024, USA

J. D. F. Habbema
Dept. of Public Health and Social Medicine, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands

J. L. Haybittle
MRC Cancer Trials Office, Hills Road, Cambridge CB2 2QH, UK

C. Hennekens
Channing Laboratories, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA

N. Keiding
Statistical Research Unit, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark

J. C. Kleinman
Division of Analysis, National Center for Health Statistics, 3700 East-West Highway, Hyattsville, MD 20782, USA

E. G. Knox
Dept. of Social Medicine, The Medical School, Birmingham B15 2TJ, UK

P. A. Lachenbruch
Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA 90024, USA

J. A. Lewis
ICI Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

E. Marubini
Istituto di Biometria e Statistica Medica, Università degli studi di Milano, Via G Venezian 1, 20133 Milan, Italy

C. K. McPherson
Dept. of Community Medicine and General Practice, Gibson Lab. Building, Radcliffe Infirmary, Oxford OX2 6HE, UK

A. B. J. Nix
Department of Mathematical Statistics and Operational Research, University College, PO Box 78, Cardiff CF1 1XL, UK

B. S. Pasternack
Dept. of Environmental Medicine New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA

S. J. Pocock
Dept. of Clinical Epidemiology and General Practice, Royal Free Hospital Medical School, Pond Street, London NW3 2PN, UK

A. Rimm
Biostatistics/Epidemiology Division, Dept. of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA

B. Rosner
Channing Laboratories, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA

E. Schifflers
Facultés Universitaires N.-D. de la Paix, Département de Mathématique, B-5000 Namur, Belgium

D. Siegel
National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA

R. J. Simes
Ludwig Institute for Cancer Research, Blackburn Building, University of Sydney, Sydney, New South Wales 2000, Australia

R. Simon
Biometric Research Branch National Cancer Institute, National Cancer Institute, Bethesda, MD 20892, USA

D. J. Spiegelhalter
MRC Biostatistics Unit, 5 Shaftesbury Road, Cambridge CB2 2BW, UK

I. Sutherland
MRC Biostatistics Unit, 5 Shaftesbury Road, Cambridge CB2 2BW, UK

J. Wittes
Mathematical and Applied Statistics Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20205, USA

R. Zentgraf
Gödecke Aktiengesellschaft, Postfach 569, Mooswaldallee 1-9, 7800 Freiburg, Germany

WILEY

SMEDDA 7 1–1324 (1988)
ISSN 0277–6715

Copyright © 1988 John Wiley & Sons Ltd

COPYING OF ARTICLES

The code and the copyright notice appearing at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, on the condition that the copier pay for the copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The per-copy fee for each article appears after the dollar sign, and is to be paid through the Copyright Clearance Center, Inc. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Such permission requests, or other inquiries, should be addressed to the publisher.

Photo Typeset by Macmillan India Ltd. Printed by Page Bros (Norwich) Ltd., Norwich, U.K.

CONTENTS

Volume 7, Issue Nos. 1–12

STATISTICS IN MEDICINE

Issue No. 1/2, January–February 1988

PROCEEDINGS OF THE WORKSHOP ON METHODS FOR LONGITUDINAL DATA ANALYSIS IN EPIDEMIOLOGICAL AND CLINICAL STUDIES, SEPTEMBER 1986

Sponsored by the National Heart, Lung and Blood Institute, Bethesda, Maryland, U.S.A.

Editorial i
Preface *M. C. Wu and J. W. Kusek* 1
List of Speakers and Discussants 3
Chairman's Introduction *N. Breslow* 7

METHODS FOR ANALYSING REPEATED MEASUREMENTS

The Use of Lung Function Tests in Identifying Factors that Affect Lung Growth and Aging *A. S. Buist and W. M. Vollmer* 11
A Comparative Study of Three Methods for Analysing Longitudinal Pulmonary Function Data *J. E. Diem and J. R. Liukkonen* 19
General Methods for Analysing Repeated Measures *T. A. Louis* 29
A Longitudinal View of Blood Pressure During Childhood: The Muscatine Study *R. M. Lauer and W. R. Clarke* 47
Autoregressive Modelling for the Analysis of Longitudinal Data with Unequally Spaced Examinations *B. Rosner and A. Muñoz* 59
Autoregressive Growth Curves and Kalman Filtering *P. D. Wilson* 73
Discussion 87

REPEATED CATEGORICAL RESPONSE

Issues in the Analysis of Repeated Categorical Outcomes *J. H. Ware, S. Lipsitz and F. E. Speizer* 95
Some General Methods for the Analysis of Categorical Data in Longitudinal Studies *J. R. Landis, M. E. Miller, C. S. Davis and G. G. Koch* 109
Analysing Repeated Measurements with Possibly Missing Observations by Modelling Marginal Distributions *L. J. Wei and D. O. Stram* 139
Likelihood Analysis of Multi-state Models for Disease Incidence and Mortality *J. D. Kalbfleisch and J. F. Lawless* 149
Commentary *S. L. Zeger* 161
Discussion 169

Indexed or abstracted by 'BIOSIS', 'Cambridge Scientific Abstracts', 'Chronic Diseases in Canada', 'Current Awareness in Biological Sciences', 'Current Contents', 'Current Index to Statistics', 'Engineering in Medicine and Biology', 'Excerpta Medica', 'Executive Sciences Inst. Inc.', 'Paediatric and Perinatal Epidemiology', 'Statistical Theory and Method Abstracts'.

SPECIAL TOPICS

Report of a Workshop on Statistical Issues in Longitudinal Studies of Health. Held in Berlin (West), 23–26 June 1986 *J. H. Dwyer and M. Feinleib* 177
Familial Aggregation in the Presence of Temporal Trends *M. A. Province and D. C. Rao* 185
Discussion 199

RISK FACTORS AND SURVIVAL

Comparison of Baseline and Repeated Measure Covariate Techniques in the Framingham Heart Study *L. A. Cupples, R. B. D'Agostino, K. Anderson and W. B. Kannel* 205
Commentary on 'Comparison of Baseline and Repeated Measure Covariate Techniques in the Framingham Heart Study' *R. D. Abbott* 219
Effect of Cigarette Smoking in Epidemiological Studies of Lung Cancer *A. S. Whittemore* 223
Models of the Interaction of Mortality and the Evolution of Risk Factor Distribution: A General Stochastic Process Formulation *K. G. Manton, M. A. Woodbury and E. Stallard* 239
Effects of Mismodelling and Mismeasuring Explanatory Variables on Tests of their Association with a Response Variable *S. W. Lagakos* 257
Aspects of the Use of Relative Risk Models in the Design and Analysis of Cohort Studies and Prevention Trials *R. L. Prentice and S. G. Self* 275
Commentary *M. Halperin* 289
Commentary *K. G. Manton, M. A. Woodbury and E. Stallard* 293
Discussion 297

ANALYSIS OF DATA WITH MISSING VALUES

Missing Data in Longitudinal Studies *N. M. Laird* 305
Analysis of Incomplete Multivariate Data using Linear Models with Structured Covariance Matrices *M. D. Schluchter* 317
Estimating Hidden Morbidity via its Effect on Mortality and Disability *M. A. Woodbury, K. G. Manton and A. I. Yashin* 325
Analysing Changes in the Presence of Informative Right Censoring Caused by Death and Withdrawal *M. C. Wu and K. Bailey* 337
Commentary *R. J. A. Little* 347
Discussion 357
Chairman's Concluding Remarks *N. Breslow* 361

Issue No. 3, March 1988

Sample Size and Power for Case-control Studies when Exposures are Continuous 363
J. H. Lubin, M. H. Gail and A. G. Ershow

Estimating Reference Ranges in Clinical Pathology: an Objective Approach 377
S. Merkouriou and D. Dix

Testing for a Change-point in Registry Data with an Example on Hypospadias 387
J. M. Simpkin and D. Y. Downham

A Model-based Approach to Characterize the Incubation Period of Paediatric Transfusion-associated Acquired Immunodeficiency Syndrome 395
K.-J. Lui, T. A. Peterman, D. N. Lawrence and J. R. Allen

Assessing Diagnostic Reliability and Estimating Incidence Rates Associated with a Strictly Progressive Disease: Dental Caries 403
M. A. Espeland, W. C. Murphy and D. H. Leverett

Correcting for Selection Bias in Estimation of Within-individual Variance 417
P. D. Wilson

The Probability that Long-term Mean Diastolic Blood Pressure is Extreme: Tables for Black Individuals 423
P. D. Wilson and J. R. Hebel

Multinomial Regression Models Based on Continuation Ratios 435
C. Cox

Investigation of the Associations of a Number of HLA Antigens with Psoriasis and Psoriatic Arthritis 443
J. Green, M. Montasser, H. C. Low and J. C. Woodrow

LETTER TO THE EDITOR 451

ANNOUNCEMENT 452

BOOK REVIEWS 453

Issue No. 4, April 1988

Loss of Power from an Optimistic Alternative Hypothesis 457
L. E. Blumenson

A Note on Sample Size Computation for Testing Interactions 467
P. A. Lachenbruch

Some Analysis Strategies for Three-period Changeover Designs with Two Treatments 471
K. B. Hafner, G. G. Koch and A. T. Canada

The Analysis of Survival Data from a Central Cancer Registry with Passive Follow-up 483
G. M. Tallis, P. Leppard and T. J. O'Neill

Density Equalized Map Projections: a Method for Analysing Clustering around a Fixed Point 491
J. Schulman, S. Selvin and D. W. Merrill

Summary Attributable Risk Estimation from Unmatched Case-control Data 507
S. J. Kuritz and J. R. Landis

Evaluating the Discriminatory Power of a Multiple Logistic Regression Model 519
M. S. Green

An Uncertainty Measure in Logistic Discrimination 525
E. Lesaffre and A. Albert

Descriptive Statistical Analyses of Serial Dilution Data 535
M. A. Hamilton and M. G. Rinaldi

BOOK REVIEW 545

ANNOUNCEMENTS 547

Issue No. 5, May 1988

Multiple Reading Procedures: the Performance of Diagnostic Tests 549
P. A. Lachenbruch

Planning the Size of Survival Time Clinical Trials with Allowance for Stratification 559
M. A. A. Moussa

Optimal Two-stage Designs for Clinical Trials with Binary Response 571
P. F. Thall, R. Simon, S. S. Ellenberg and R. Shrager

A Random Walk Model for Evaluating Clinical Trials Involving Serial Observations 581
J. L. Hopper and G. P. Young

Contingency Table Estimation of Genetic Parameters and Disease Risks 591
H. J. Khamis

Smoothing Methods for Epidemiologic Analysis 601
M. R. Segal, S. T. Weiss, F. E. Speizer and I. B. Tager

Proportional Hazards Models for Average Data for Groups 613
A. J. Dobson

Prospective Epidemiological Studies Involving Paired Organs 619
J. Whitehead and C. Dorse

ANNOUNCEMENT 627

Issue No. 6, June 1988

The Hidden Effect of Time 629
D. G. Altman and J. P. Royston

A New Method of Estimation of Interobserver Variation and its Application to the Radiological Assessment of Osteoarthrosis in Hip Joints 639
P. Kjærsgaard-Andersen, F. Christensen, S. A. Schmidt, N. W. Pedersen and B. Jørgensen

Investigations of Excess Environmental Risks around Putative Sources: Statistical Problems and a Proposed Test 649
R. A. Stone

Multistate Models in Survival Analysis: a Study of Nephropathy and Mortality in Diabetes 661
P. K. Andersen

Modelling the Liver Function Data in Diabetes 671
T. T. Chen

Longitudinal Versus Cross-sectional Estimation of Lung Function Decline—Further Insights 685
W. M. Vollmer, L. R. Johnson, L. E. McCamant and A. S. Buist

The Statistical Analysis of Treatment Effects in 24-hour Ambulatory Blood Pressure Recordings 697
M. R. Marler, R. G. Jacob, J. P. Lehoczky and A. P. Shapiro

The Extrapolation of Attributable Risk to New Populations 717
J. H. Ellenberg

Issue No. 7, July 1988

Improving the Aggregate Performance of Psychiatric Diagnostic Methods when not all Subjects Receive the Standard Test 727
P. W. Lavori and M. B. Keller

Instrumental Variables in the Evaluation of Diagnostic Test Procedures when the True Disease State is Unknown 739
N. J. D. Nagelkerke, V. Fidler and M. Buwalda

Variance Estimation for Epidemiologic Effect Estimates Under Misclassification 745
S. Greenland

Sample Size Requirements for Studies Estimating Odds Ratios or Relative Risks 759
S. Lemeshow, D. W. Hosmer, Jr and J. Klar

Exact Versus Asymptotic Analysis for a Matched Case-control Study 765
K. F. Hirji, R. M. Elashoff, D. H. Moore, II and D. E. Bennett

Confidence Intervals for Causal Parameters 773
J. M. Robins

A Markov Process Interpretation of Sullivan's Index of Morbidity and Mortality 787
S. C. Newman

A Computer Enhanced Runs Test for Smoothed Data 795
B. P. Katz

'Optimal' Designs for Drug, Neurotransmitter and Hormone Receptor Assays 805
G. Dunn

BOOK REVIEWS 817

Issue No. 8, August 1988

The Analysis of Event History Data: a Review of Progress and Outstanding Problems 819
D. Clayton

Identifying Prognostic Factors in Binary Outcome Data: an Application Using Liver Function Tests and Age to Predict Liver Metastases 843
R. W. Makuch, P. S. Rosenberg and J. Mulshine

A New Calculation of the Carcinogenic Risk of Obstetric X-raying 857
J. F. Bithell and C. A. Stiller

Confidence Interval Estimation of a Rate and the Choice of Sample Size 865
D. Böhning

Designing a Clinical Trial to Demonstrate Prevention of Ulcer Recurrence: Modelling Simulation Approaches 877
J. D. Elashoff, G. G. Koch and G. Y. H. Chi

A Note on Graphical Presentation of Estimated Odds Ratios from Several Clinical Trials 889
R. F. Galbraith

The Parameters of Death: a Consideration of the Quantity of Information in a Life Table using a Polynomial Representation of the Survivorship Curve 895
J. Anson

Issue No. 9, September 1988

Editorial Announcement 913

Methods for Assessing whether Change Depends on Initial Value 915
R. J. Hayes

Comparing Incomplete Paired Binomial Data under Non-random Mechanisms 929
S. C. Choi and D. M. Stablein

Correcting for the Bias Caused by Drop-outs in Hypertension Trials 941
G. D. Murray and J. G. Findlay

Prediction of Outcome of Anaesthesia in Patients over 40 Years: a Multifactorial Risk Index 947
L. Tiret, F. Hatton, J. M. Desmonts and G. Vourc'h

Exposure–response Relationship for a Dichotomized Response when the Continuous Underlying Variable is not Measured 955
L. M. Irwig and H. T. Groeneveld

Two-process Models for Discrete-time Serial Categorical Response 965
R. Dersimonian and S. G. Baker

Latent Variable Models for the Analysis of Medical Data with Repeated Measures of Binary Variables 975
L. Blackwood

Correspondence Analysis and Logistic Modelling: Complementary use in the Analysis of a Health Survey Among Nurses 983
A. Leclerc, D. Luce, F. Lert, J. F. Chastang and P. Logeay

LETTERS TO THE EDITOR 997

BOOK REVIEW 1001

Issue No. 10, October 1988

Interactions Between Statisticians and Biomedical Journal Editors 1003
R. G. Marks, E. K. Dawson-Saunders, J. C. Bailar, B. B. Dan and J. A. Verran

Comparing the Effects of Different Durations of the Same Therapy 1013
L. S. Freedman and B. L. de Stavola

A Statistical Methodology for Postmarketing Surveillance of Adverse Drug Reaction Reports 1023
P. K. Norwood and A. R. Sampson

Identifying Important Results from Multiple Statistical Tests 1031
R. A. Parker and R. B. Rothenberg

Application of Multiple Time Series Analysis to the Estimation of Pneumonia and Influenza Mortality by Age 1962–1983 1045
D. F. Stroup, S. B. Thacker and J. L. Herndon

Forecasting the Demand on Accident and Emergency Departments in Health Districts in the Trent Region 1061
P. C. Milner

The Effect of Non-differential Exposure Misclassification on Estimates of the Attributable and Prevented Fraction 1073
C.-C. Hsieh and S. D. Walter

Examining Neighbourhood Confounding in a Survey: An Example using the National Health and Nutrition Examination Survey II 1087
E. L. Korn and B. I. Graubard

LETTER TO THE EDITOR 1099

ANNOUNCEMENT 1103

Issue No. 11, November 1988

Papers from the International Society for Clinical Biostatistics
Eighth International Meeting, September 1987

Preface 1105

The ISCB 1107

Drug Treatment of Mild Hypertension to Reduce the Risk of CHD: is it Worth-while? 1109
I. Holme

Heterogeneity in Survival Analysis 1121
O. O. Aalen

Remission Duration: an Example of Interval-censored Observations 1139
G. Rücker and D. Messerer

Modelling the 1985 Influenza Epidemic in France 1147
A. Flahault, S. Letrait, P. Blin, S. Hazout, J. Ménarés and A. J. Valleron

A Test to Detect Clustering Applied to Muscle Fibres 1157
D. Howel

Improving the Quality of Data in Randomized Clinical Trials: The Compact Computer Package 1165
C. E. D. Chilvers, P. M. Fayers, L. S. Freedman, R. M. Greenwood, D. Machin, N. Palmer and A. J. Westlake

Prescription Sequence Analysis: A New and Fast Method for Assessing Certain Adverse Reactions of Prescription Drugs in Large Populations 1171
H. Petri, H. C. W. de Vet, J. Naus and J. Urquhart

REGULAR PAPERS

Explanatory and Pragmatic Estimates of the Treatment Effect when Deviations from Allocated Treatment Occur 1179
R. G. Newcombe

Optimal Placebo Response Rates for Comparing Two Binomial Proportions 1187
S. J. Day

Sample Size Formulae for Intervention Studies with the Cluster as Unit of Randomization 1195
F. Y. Hsieh

LETTER TO THE EDITOR 1203

BOOK REVIEW 1204

ANNOUNCEMENT 1205

Issue No. 12, December 1988

Inborn/outborn Status and Neonatal Survival: A Meta-analysis of Non-randomized Studies 1207
R. J. Ozminkowski, P. M. Wortman and D. W. Roloff

Bayesian Analysis of Case-control Studies 1223
R. J. Marshall

Stopping Rules and Estimation Problems in Clinical Trials 1231
M. D. Hughes and S. J. Pocock

A Quantitative Study of the Bias in Estimating the Treatment Effect Caused by Omitting a Balanced Covariate in Survival Models 1243
C. Chastang, D. Byar and S. Piantadosi

Non-parametric Analysis of Treatment–Covariate Interaction in the Presence of Censoring 1257
M. Schemper

A Statistical Assessment of Clinical Equivalence 1267
J. Mau

On Sample Sizes to Estimate the Protective Efficacy of a Vaccine 1279
R. T. O'Neill

Beyond Sensitivity, Specificity and Statistical Independence 1289
R. H. Jones and M. W. McClatchey

Doubling the One-sided *P*-value in Testing Independence in 2×2 Tables Against a Two-sided Alternative 1297
C. J. Lloyd

BOOK REVIEWS 1307

Acknowledgement 1311

Author Index 1313

Subject Index 1315